BackgroundThis randomized controlled trial was aimed to evaluate the combined efficacy of injectable platelet‐rich fibrin (i‐PRF) and scaling and root planing (SRP) in type 2 diabetes mellitus subjects having periodontitis.MethodsTwenty‐six Stage III, grade C periodontitis subjects (HbA1c > 7) were recruited in this split‐mouth study. Following SRP, the test sites received subgingival application of i‐PRF, while the control sites received saline. Plaque index, bleeding on probing, modified gingival index, probing pocket depth (PPD) and clinical attachment level (CAL) were measured at baseline, 3 and 6 months.ResultsTwenty‐three participants completed the course of research. The Friedman test followed by Dunn's post hoc test, revealed significant improvement in all the clinical parameters from baseline to 3 and 6 months in both the study groups (p ≤ 0.05). The mean PPD and CAL decreased from 6.30 ± 1.25 and 7.48 ± 1.75 at baseline to 3.48 ± 1.34 and 4.39 ± 1.67 at 6 months in control sites and from 6.57 ± 1.56 and 7.61 ± 1.69 to 3.39 ± 1.23 and 4.26 ± 1.81 at 6 months in test sites (p ≤ 0.0001). Intergroup analysis found no statistical significant differences in the evaluated parameters across all time intervals (p > 0.05)ConclusionThe results indicated that the adjunctive application of i‐PRF to SRP provided similar benefits as saline and SRP in diabetes mellitus subjects.Key Points
Question: To find the combined efficacy of injectable platelet‐rich fibrin (i‐PRF) along with scaling and root planing (SRP) in the management of periodontal pockets of Stage III and Grade C periodontitis patients having Type 2 Diabetes Mellitus (T2DM).
Finding: All of the treated sites showed satisfactory healing. Both the treatment modalities (i‐PRF + SRP and Saline + SRP) were effective in the treatment of periodontal pockets. At 3 and 6 months, there were no significant differences in periodontal parameters between groups.
Meaning: The application of i‐PRF as an adjunct to SRP provided similar benefits as saline and SRP in improving clinical parameters in subjects with stage III and grade C periodontitis patients having T2DM (HbA1C > 7).